Industry News
Bausch + Lomb Acquires AcuFocus
Bausch + Lomb has acquired AcuFocus, a privately held ophthalmic medical device company, through a merger transaction.
AcuFocus has developed the IC-8® Apthera™ intraocular lens (IOL), which was approved by the FDA in July 2022. It is the first small aperture non-toric extended depth of focus IOL for cataract patients with up to 1.5 diopters of corneal astigmatism. The IC-8 Apthera lens features proprietary small aperture technology that corrects both distance and near vision, addressing the effects of presbyopia.
“Cataracts are the largest contributor to global blindness in adults aged 50 years and older, with more than 15 million individuals, or approximately 45 percent of the more than 33 million cases of global blindness. We believe that the IC-8 Apthera EDOF IOL will bolster our surgical portfolio by enhancing our IOL offerings, which is a strategic area of focus for Bausch + Lomb,” said Joseph C. Papa, CEO, Bausch + Lomb. “We will continue to focus on areas of unmet medical need that we believe will help drive long-term growth in our core segments, and importantly, help us achieve our mission of helping people see better to live better.”
"Bausch + Lomb is a legacy name in eye care with a fully integrated portfolio of offerings in eye health,” said Al Waterhouse, president and CEO, AcuFocus. “With its extensive development footprint and renowned commercial expertise, we believe Bausch + Lomb is best positioned to educate physicians about the IC-8 Apthera lens, and ultimately, ensure more cataract patients have access to this new IOL.”
The global premium cataract IOL market is projected to grow 13% annually between 2022-2027.
